DocWire News Editors

DocwireNews

Results from a new study presented at the 2018 annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals indicated that treatment with secukinumab (SEC) was associated with a low incidence of immunogenicity over 52 weeks in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS), similar to results seen in patients with plaque psoriasis.The researchers, led by Atul A. Deodhar, MD, of Oregon Health and Science University in Portland, examined immunogenicity with SEC, a fully human monoclonal IgG1 antibody that selectively targets interleukin-17A, because monoclonal antibody therapies may be associated with immunogenicity and the production of anti-drug antibodies. This can lead to adverse events and/or affect drug pharmacokinetics and clinical response.The sample included 1,414 patients with PsA who were receiving SEC in the FUTURE studies, as well as 1,163 patients with AS who were receiving SEC in the MEASURE studies. Patients were evaluated for immunogenicity at baseline and at weeks 16 (patients with AS only), 24, and 52. If anti-drug antibodies were found, the researchers analyzed the samples through week 52 for drug-neutralizing potential, immunogenicity-related adverse events, and impact on SEC pharmacokinetics and efficacy.In the PsA group, five patients (0.35%) developed anti-drug antibodies; in the AS group, eight patients (0.68%) developed them. The researchers did not observe any associations between the presence of anti-drug antibodies and SEC dose, frequency, or mode of administration. In addition, anti-drug antibodies had a neutralizing effect in only one patient (from the PsA group). They were not associated with any immunogenicity-related adverse events. Overall, patients with anti-drug antibodies had normal secukinumab pharmacokinetics and did not lose treatment efficacy over 52 weeks.

Jordana Jampel

Glycan-Targeting Novel Vaccine Shows Promise for Vast Virus Protection

Infectious Disease

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Latest News

Research Finds Low Immunogenicity with Secukinumab in Patients with Psoriatic Arthritis or Ankylosing Spondylitis

ACR 2018 Conference

Results from a new study presented at the 2018 annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals indicated that treatment ...

Research Finds Low Immunogenicity with Secukinumab in Patients with Psoriatic Arthritis or

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe